Pharmagreen Biotech Inc. (PHBI)
OTHER OTC:PHBI
Top Page
No summary available
Positive Factors
Proprietary Technology
The use of proprietary technology like 'Chibafreen' provides a competitive edge by ensuring high-quality, disease-free plantlets, crucial for consistent crop yields in the cannabis industry.
Negative Factors
Negative Equity
Negative equity reflects financial instability, limiting the company's ability to secure financing and invest in growth, posing a risk to long-term operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Technology
The use of proprietary technology like 'Chibafreen' provides a competitive edge by ensuring high-quality, disease-free plantlets, crucial for consistent crop yields in the cannabis industry.
Read all positive factors
Pharmagreen Biotech (PHBI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$929.10K
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue Growth-47.07%
EPS Growth42.86%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding663,645,750
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)-0.90
Price to Sales (P/S)812.27
P/FCF Ratio-98.62
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue661.61
Enterprise Value/Gross Profit-1.83K
Enterprise Value/Ebitda-5.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharmagreen Biotech Business Overview & Revenue Model
Company Description
Pharmagreen Biotech Inc., a biotech sciences solutions company, focuses on the production of starter plantlets for CBD hemp and medical cannabis industries. The company was incorporated in 2007 and is headquartered in Coquitlam, Canada....
How the Company Makes Money
Pharmagreen Biotech generates revenue through the sale of tissue cultured starter plantlets to commercial cannabis growers. The company employs a B2B model, catering specifically to businesses that require high-quality and consistent plant materia...
Pharmagreen Biotech Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Sep 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Sep 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.80K | 3.41K | 3.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -652.00 | 1.74K | -6.45K | 0.00 | -435.00K | -435.00K |
| EBITDA | -199.40K | -971.18K | 26.36K | 194.27K | -3.76M | -677.00K |
| Net Income | -234.38K | -1.00M | -569.00K | -875.00K | -4.53M | -2.44M |
Balance Sheet | ||||||
| Total Assets | 96.60K | 97.68K | 121.57K | 208.97K | 373.08K | 266.25K |
| Cash, Cash Equivalents and Short-Term Investments | 568.00 | 276.00 | 1.25K | 8.02K | 25.30K | 12.20K |
| Total Debt | 354.33K | 356.24K | 372.84K | 338.59K | 270.20K | 714.55K |
| Total Liabilities | 2.67M | 3.23M | 2.30M | 2.03M | 2.07M | 3.20M |
| Stockholders Equity | -2.52M | -3.09M | -2.13M | -1.78M | -1.65M | -2.89M |
Cash Flow | ||||||
| Free Cash Flow | -19.00K | -28.09K | -73.84K | -426.57K | -206.08K | -607.63K |
| Operating Cash Flow | -19.00K | -28.09K | -73.84K | -426.57K | -206.08K | -607.63K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 25.71K | 28.55K | 83.37K | 313.71K | 257.50K | 562.62K |
Pharmagreen Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $929.10K | -0.33 | ― | ― | -47.07% | 42.86% | |
51 Neutral | $8.09M | -1.12 | -71.27% | ― | -72.15% | -223.62% | |
44 Neutral | $1.99M | -0.18 | -145.52% | ― | ― | 97.70% | |
40 Underperform | $404.68K | -2.13 | ― | ― | -8.57% | -52.17% |
* Healthcare Sector Average
PHBI
Pharmagreen Biotech
―
―
―
ADTX
Aditxt
0.52
-2,711.48
-99.98%
ADXN
Addex Therapeutics
6.48
-0.03
-0.46%
MSPR
MSP Recovery
0.03
-9.63
-99.71%
BJDX
Bluejay Diagnostics
2.05
-7.87
-79.33%
AKAN
Akanda Corp
0.69
-16.50
-95.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―